Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind double-dummy study of intravenous empasiprubart versus intravenous immunoglobulin in adults with chronic inflammatory demyelinating polyradiculoneuropathy
MOH_2025-11-25_015493Phase 3Not yet recruiting
- Sponsor
- argenx
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of empasiprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) (3 arms), sponsored by argenx. Primary endpoint: Functional ability improvement. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
empasiprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on MOH_2025-11-25_015493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-25_015493.